P
Philip J. Rosenfeld
Researcher at University of Miami
Publications - 358
Citations - 32577
Philip J. Rosenfeld is an academic researcher from University of Miami. The author has contributed to research in topics: Macular degeneration & Optical coherence tomography. The author has an hindex of 77, co-authored 325 publications receiving 28506 citations. Previous affiliations of Philip J. Rosenfeld include Massachusetts Eye and Ear Infirmary & Johns Hopkins University School of Medicine.
Papers
More filters
Journal ArticleDOI
Correlations Between Different Choriocapillaris Flow Deficit Parameters in Normal Eyes Using Swept Source OCT Angiography.
Yingying Shi,Qinqin Zhang,Fang Zheng,Jonathan F. Russell,Elie H. Motulsky,James T. Banta,Zhongdi Chu,Hao Zhou,Nimesh A. Patel,Luis de Sisternes,Mary K Durbin,William J. Feuer,Giovanni Gregori,Ruikang K. Wang,Philip J. Rosenfeld +14 more
TL;DR: Excellent correlations between FDa and FD% in regions from 3x3 mm and 6x6 mm scans are found when measuring CC FDs, and further studies are needed to determine if one parameter is more useful when studying diseased eyes.
Journal ArticleDOI
Increase in translatable mRNA for mitochondrial pyruvate carboxylase during differentiation of 3T3 preadipocytes.
TL;DR: It appears that the differentiation-induced rise in the cellular level of pyruvate car boxylase results from an increased rate of carboxylase synthesis due to a rise inThe level of translatable carboxyase messenger RNA.
Journal ArticleDOI
Lessons from Recent Phase III Trial Failures: Don't Design Phase III Trials Based on Retrospective Subgroup Analyses from Phase II Trials.
TL;DR: Upon closer inspection of these 3 failed phase III trials, it was found that they did not adhere to 2 basic rules of drug development that should provide the best chance of a phase III trial success.
Journal ArticleDOI
Retinal toxicity of commercially available intravitreal ketorolac in albino rabbits.
TL;DR: Commercially available ketorolac tromethamine was found to be toxic to the retinas of albino rabbits following multiple intravitreal injections at a dose of 3 mg while no electrophysiologic toxicity was found.
Journal ArticleDOI
APEX: a phase II randomised clinical trial evaluating the safety and preliminary efficacy of oral X-82 to treat exudative age-related macular degeneration.
Michael N. Cohen,Denis O'Shaughnessy,Kate Fisher,Jennifer Cerami,Carl C. Awh,Daniel E Salazar,Philip J. Rosenfeld,Jeffrey S. Heier +7 more
TL;DR: X-82 oral therapy in combination with pro re nata anti-VEGF injections showed non-inferiority in visual acuity outcomes while achieving a dose-dependent decrease in the number of anti-VeGF injections compared with placebo.